SCHEMBL5380498

SCHEMBL5380498

[N-]=[N+]=CC(=O)OC/C=C/c1c(F)cc(NC(=O)OCc2ccccc2)cc1F

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MGLL Q99685 3/20 0.43
POLB P06746 1/20 0.42
PTGDR2 Q9Y5Y4 1/20 0.40
ENPP2 Q13822 2/20 0.40
TP53 P04637 2/20 0.40
MAPT P10636 2/20 0.40
NPC1 O15118 1/20 0.40
ALDH1A1 P00352 1/20 0.40
TSHR P16473 1/20 0.40
RAB9A P51151 1/20 0.40
ATM Q13315 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
PTPN1 P18031 1/20 0.38
KCNA5 P22460 1/20 0.38
KDM1A O60341 1/20 0.38
MAOA P21397 1/20 0.38
MAOB P27338 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5380507 1.00 MGLL (0.43) MGLLPOLBPTGDR2ENPP2TP53
SCHEMBL4883952 0.88 MGLL (0.44) MGLLPOLBPTGDR2ENPP2TP53
SCHEMBL4883956 0.88 MGLL (0.44) MGLLPOLBPTGDR2ENPP2TP53
SCHEMBL4871675 0.83 POLB (0.48) MGLLPOLBENPP2TP53MAPT
SCHEMBL4871687 0.83 POLB (0.48) MGLLPOLBENPP2TP53MAPT
SCHEMBL14370629 0.82 MGLL (0.51) MGLLPOLBPTGDR2ENPP2TP53
SCHEMBL4879348 0.81 KDM4E (0.35) MAPTNPC1TSHRRAB9ASMN1; SMN2
SCHEMBL4879337 0.81 KDM4E (0.35) MAPTNPC1TSHRRAB9ASMN1; SMN2
SCHEMBL5374821 0.78 MGLL (0.52) MGLLPOLBPTGDR2ENPP2TP53
SCHEMBL5374818 0.78 MGLL (0.52) MGLLPOLBPTGDR2ENPP2TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7279494-B2 Antimicrobial [3.1.0] bicyclohexylphenyl-oxazolidinone derivatives and analogues PFIZER INC. (US) 2007-10-09 US disclosed
US-7279494-B2 Antimicrobial [3.1.0] bicyclohexylphenyl-oxazolidinone derivatives and analogues PFIZER INC. (US) 2007-10-09 US disclosed
EP-1615916-A1 ANTIMICROBIAL 3.1.0 BICYCLOHEXYLPHENYL-OXAZOLIDINONE DERIVATIVES AND ANALOGUES Pharmacia & Upjohn Company LLC (US) 2006-01-18 EP disclosed
US-20050192325-A1 Antimicrobial [3.1.0] bicyclohexylphenyl-oxazolidinone derivatives and analogues RENSLO ADAM (US) 2005-09-01 US disclosed
WO-2004089943-A1 ANTIMICROBIAL [3.1.0] BICYCLOHEXYLPHENYL-OXAZOLIDINONE DERIVATIVES AND ANALOGUES PHARMACIA & UPJOHN COMPANY LLC (US) 2004-10-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050192325-A1 Antimicrobial [3.1.0] bicyclohexylphenyl-oxazolidinone derivatives and analogues OXA1L, CYP51A1, CYP2C19 MGLL 1507/4885POLB 979/4885PTGDR2 3720/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.